Can ÖZTÜRK, Tarkan ÖZDEMİR, Orhan KOÇ, Çiğdem ÖZDİLEKCAN, Hatice KILIÇ, H. Canan HASANOĞLU, Mustafa Hamidullah TÜRKKANI, Nilgün YILMAZ DEMİRCİ

The Geographical Distribution of Morbidity Caused By Chronic Obstructive Pulmonary Disease in Turkey: COPDTURKEY-2

Background: Chronic obstructive pulmonary disease (COPD) is oneof the most prevalent causes for morbidity and mortality, and it createsa cumulative economic and social burden.Aims: To determine the distribution of the prevalence of patients inTurkey who were diagnosed with COPD and their morbidity rates,according to the regions and cities they belong to. Moreover, the studycontributes to the prevention and cure services of COPD that shouldbe planned in the future.Study Design: A retrospective cohort.Methods: The database of the Social Security Institution from 2016has been scanned. All the data with prescription registration, with thecode ICD-10, J44.0-J44.9, which were aimed for diagnosing and/orcure, have been evaluated with a retrospective cohort.Results: In 2016, 955,369 patients who were admitted as outpatientsto the hospitals were diagnosed with COPD. The average number ofannual COPD cases that were admitted was 2.09. Twenty percent(20%) of the outpatient applications were via emergency room. Therate of hospitalization among the applicants was 17.75%, with a totalof 1,994,325. The average annual number of hospitalizations of menwas higher than that of women. The average number of hospitalizationdays was 6.52. The region with the highest prevalence of outpatientadmission and hospitalization was the Black Sea Region.Conclusion: The high rate of hospitalization was considered to be theoutcome of the insufficient “outpatient” management.

PDF

___

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J2006;27:397- 412.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med2006;3:442.
3. López-Campos JL, Tan W, Soriano JB. Global burden of COPD.Respirology. 2016;21:14-23.
4. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and cost of chronic obstructive pulmonary disease. Eur Respir J2006;27:188-207.
5. Global Strategy for The Diagnosis, Management, And Prevention of Chronic Obstructive Pulmonary Disease (2016 Report), Global Initiative for Chronic Obstructive Lung Disease (GOLD),2019.
6. Kronik Obstrüktif Akciğer Hastalığı (KOAH) Koruma, Tanı ve Tedavi Raporu, Türk Toraks Derneği KOAH Çalışma Grubu; 2014.
7. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
8. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001;68:4-19.
9. Türkiye Kronik Hava Yolu Hastalıkları Önleme ve Kontrol Programı (2014-2017), T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, Sağlık Bakanlığı Yayın No:947, Ankara; 2014.
10. Türkiye Hastalık Yükü Çalışması 2004, T.C. Sağlık Bakanlığı, Refik Saydam Hıfzıssıhha Merkezi Başkanlığı, Hıfzıssıhha Mektebi Müdürlüğü, Sağlık Bakanlığı Yayın No: 701, Ankara, 2006.
11. http://www.tuik.gov.tr/PreTablo.do?alt_id=1059
12. Souliotis K, Kani C, Papageorgiou M, Lionis D, Gourgoulianis K. Using Big Data to Assess Prescribing Patterns in Greece: The Case of Chronic Obstructive Pulmonary Disease. PLoS One 2016;11:e0154960.
13. Johansson G, Mushnikov V, Bäckström T, Engström A, Khalid JM, Wall J, et al. Exacerbations and health care resource utilization among COPD patients in a Swedish registry-based nation-wide study. BMC Pulm Med 2018;18:17.
14. LamprechtB,McBurnieMA,VollmerWM,Gudmundsson G, Welte T, NizankowskaMogilnicka E, etal.COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011;139:752-63.
15. Türkiye’de Tütün Kullanım Oranları, TürkiyeSağlıkAraştırması, 2016, Türkiye İstatistik Kurumu Haber Bülteni, Sayı: 24573, 31 Mayıs2017.
16. SağlıkİstatistikleriYıllığı 2016, TC Sağlık Bakanlığı Sağlık Araştırmaları Genel Müdürlüğü, Ankara; 2017.
17. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance--the United States, 1971-2000. MMWR SurveillSumm. 2002;51:1-16.
18. Ford ES,Croft JB,Mannino DM,Wheaton AG, Zhang X, Giles WH.COPD surveillance--United States,1999-2011. Chest 2013;144:284-305.
19. Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and burden of COPD: a population-based case-control study. PLoS One2013;8:e63285.
20. Jinjuvadia C, Jinjuvadia R, Mandapakala C, Durairajan N, Liangpunsakul S, Soubani AO. Trends in Outcomes, Financial Burden, and Mortality for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in the United States from 2002 to 2010. COPD2017;14:72-9.
21. OECD/European Union. “Average length of stay in hospital”, in Health at a Glance: Europe 2018: State of Health in the EU Cycle, OECD Publishing, Paris/European Union,Brussels; 2018.
22. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT. Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. Int J Chron Obstruct Pulmon Dis 2015;10:603-11.
23. Agboado G, Peters J, Donkin L. Factors influencing the length of hospital stay among patients resident in Blackpool admitted with COPD: a cross-sectional study. BMJ Open 2012:2.
24. Milne RJ, Beasley R. Hospital admissions for chronic obstructive pulmonary disease in New Zealand. N Z Med J 2015;128:23-35.
25. Terzano C, Colamesta V, Unit B, Romani S, Meneghini A, Volpe G, et al. Chronic obstructive pulmonary disease (COPD) exacerbation: impact of comorbidities on length and costs during hospitalization. Eur Rev Med Pharmacol Sci 2017;21:3680-9.
26. Terry DR, Nguyen H, Kim JA, Islam MR. Factors contributing to COPD hospitalisations from 2010 to 2015: Variation among rural and metropolitan Australians. Clin Respir J 2019;13:306-13.
27. Mu Z, Chen PL, Geng FH, Ren L, Gu WC, Ma JY, et al. Synergistic effects of temperature and humidity on the symptoms of COPD patients. Int J Biometeorol2017;61:1919-25.
28. https://biruni.tuik.gov.tr/bolgeselistatistik/tabloOlustur.do#
29. Almagro P, Hernandez C, Martinez-Cambor P, Tresserras R, Escarrabill J. Seasonality, ambient temperatures and hospitalizations for acute exacerbation of COPD: a population-based study in a metropolitan area. Int J Chron Obstruct Pulmon Dis. 2015;10:899-908.
30. National Institutes of Health. National Heart, Lung and Blood Institute. Morbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung and Blood Diseases,2009.
31. Sullivan SD, Strassels S, Smith DH. Characterization of the incidence and cost of COPD in the US. Eur Respir J 1996;9:421.
32. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The Costs of Treating COPD in the United States. Chest2001;119:344-52.
33. Sullivan SD, Ramsey SD, Lee TA. The Economic Burden of COPD. Chest 2000;117 (2 Suppl):5-9.